Rein, L. A. M., DeAngelo, D. J., Modena, B., Oh, S., Cridtina, B. L., Ustun, C., … Bose, P. (2024). Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis. Blood, 144(Supplement 1), 4556–4556. https://doi.org/10.1182/blood-2024-194551

Rein, Lindsay A. M., Daniel J. DeAngelo, Brian Modena, Stephen Oh, Bulai Livideanu Cridtina, Celalettin Ustun, Nathan Boggs, et al. “Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis.” Blood 144, no. Supplement 1 (November 5, 2024): 4556–4556. https://doi.org/10.1182/blood-2024-194551.

Rein LAM, DeAngelo DJ, Modena B, Oh S, Cridtina BL, Ustun C, et al. Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis. Blood. 2024 Nov 5;144(Supplement 1):4556–4556.

Rein, Lindsay A. M., et al. “Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, Nov. 2024, pp. 4556–4556. Crossref, doi:10.1182/blood-2024-194551.

Rein LAM, DeAngelo DJ, Modena B, Oh S, Cridtina BL, Ustun C, Boggs N, Manning M, Hunter AM, Akin C, Kirshenbaum A, Dybedal I, Arana Yi CY, Herrscher R, Castells M, Lansigan F, George TI, Patel J, Sun L, Shah N, Zhang J, Pilla A, Singh P, Carden M, Siebenhaar F, Bose P. Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis. Blood. American Society of Hematology; 2024 Nov 5;144(Supplement 1):4556–4556.